Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Naïve (RAN) study

Tanvir Bell, Martine Diez, Xiaoying Yu, Chi Nguyen, Claudia Kozinetz

Research output: Contribution to journalArticle

Abstract

Raltegravir and Atazanavir/ritonavir are potent first line therapeutic options for HIV treatment naïve patients. We studied raltegravir (RAL) or atazanavir/ritonavir (ATV/r) both with tenofovir/emtricitabine in a predominantly African American indigent patient population in Houston, Texas. Results from 17 patients at 48 weeks (wk); 9 in the RAL group and 8 in the ATV/r group were available for analyses. We evaluated CD4+ count, CD4%, HIV RNA viral load (VL) levels, and lipid profile at wk 0, 6, 14, 30, and 48. IL-6 and homocysteine levels were available at wk 0 and 48. Among the lipid panel between the 2 groups, triglycerides became statistically significantly lower in the raltegravir group at 14 weeks and persisted at a lower level through 48 wk. There were no significant differences in CD4+ cell count, CD4%, log VL, total cholesterol, LDL, HDL, IL-6, and homocyseine levels. Both RAL and ATV/r in combination with tenofovir/emtricitabine provide similar immunologic and virologic efficacy. There was a slight difference observed in changes in triglyceride levels but other lipid changes were similar. IL-6 and homocystine levels changed to a similar degree with these potent antiretroviral regimens.

Original languageEnglish (US)
JournalJournal of AIDS and Clinical Research
Volume4
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Ritonavir
Tenofovir
Biomarkers
Lipids
Interleukin-6
CD4 Lymphocyte Count
Viral Load
Triglycerides
Homocystine
HIV
Homocysteine
Poverty
African Americans
LDL Cholesterol
HDL Cholesterol
Atazanavir Sulfate
Raltegravir Potassium
RNA
Therapeutics
Population

Keywords

  • Antiretroviral therapy
  • Biomarkers
  • Lipid levels
  • Minority population
  • Naive therapy

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases
  • Virology

Cite this

Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Naïve (RAN) study. / Bell, Tanvir; Diez, Martine; Yu, Xiaoying; Nguyen, Chi; Kozinetz, Claudia.

In: Journal of AIDS and Clinical Research, Vol. 4, No. 2, 02.2013.

Research output: Contribution to journalArticle

@article{f85cd27d29a843ff8d008c6c85f6c8cc,
title = "Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Na{\"i}ve (RAN) study",
abstract = "Raltegravir and Atazanavir/ritonavir are potent first line therapeutic options for HIV treatment na{\"i}ve patients. We studied raltegravir (RAL) or atazanavir/ritonavir (ATV/r) both with tenofovir/emtricitabine in a predominantly African American indigent patient population in Houston, Texas. Results from 17 patients at 48 weeks (wk); 9 in the RAL group and 8 in the ATV/r group were available for analyses. We evaluated CD4+ count, CD4{\%}, HIV RNA viral load (VL) levels, and lipid profile at wk 0, 6, 14, 30, and 48. IL-6 and homocysteine levels were available at wk 0 and 48. Among the lipid panel between the 2 groups, triglycerides became statistically significantly lower in the raltegravir group at 14 weeks and persisted at a lower level through 48 wk. There were no significant differences in CD4+ cell count, CD4{\%}, log VL, total cholesterol, LDL, HDL, IL-6, and homocyseine levels. Both RAL and ATV/r in combination with tenofovir/emtricitabine provide similar immunologic and virologic efficacy. There was a slight difference observed in changes in triglyceride levels but other lipid changes were similar. IL-6 and homocystine levels changed to a similar degree with these potent antiretroviral regimens.",
keywords = "Antiretroviral therapy, Biomarkers, Lipid levels, Minority population, Naive therapy",
author = "Tanvir Bell and Martine Diez and Xiaoying Yu and Chi Nguyen and Claudia Kozinetz",
year = "2013",
month = "2",
doi = "10.4172/2155-6113.1000192",
language = "English (US)",
volume = "4",
journal = "Journal of AIDS and Clinical Research",
issn = "2155-6113",
publisher = "OMICS Publishing Group",
number = "2",

}

TY - JOUR

T1 - Lipid and biomarker differences between Raltegravir and Atazanavir/Ritonavir at 48 Weeks in the Raltegravir Atazanavir Naïve (RAN) study

AU - Bell, Tanvir

AU - Diez, Martine

AU - Yu, Xiaoying

AU - Nguyen, Chi

AU - Kozinetz, Claudia

PY - 2013/2

Y1 - 2013/2

N2 - Raltegravir and Atazanavir/ritonavir are potent first line therapeutic options for HIV treatment naïve patients. We studied raltegravir (RAL) or atazanavir/ritonavir (ATV/r) both with tenofovir/emtricitabine in a predominantly African American indigent patient population in Houston, Texas. Results from 17 patients at 48 weeks (wk); 9 in the RAL group and 8 in the ATV/r group were available for analyses. We evaluated CD4+ count, CD4%, HIV RNA viral load (VL) levels, and lipid profile at wk 0, 6, 14, 30, and 48. IL-6 and homocysteine levels were available at wk 0 and 48. Among the lipid panel between the 2 groups, triglycerides became statistically significantly lower in the raltegravir group at 14 weeks and persisted at a lower level through 48 wk. There were no significant differences in CD4+ cell count, CD4%, log VL, total cholesterol, LDL, HDL, IL-6, and homocyseine levels. Both RAL and ATV/r in combination with tenofovir/emtricitabine provide similar immunologic and virologic efficacy. There was a slight difference observed in changes in triglyceride levels but other lipid changes were similar. IL-6 and homocystine levels changed to a similar degree with these potent antiretroviral regimens.

AB - Raltegravir and Atazanavir/ritonavir are potent first line therapeutic options for HIV treatment naïve patients. We studied raltegravir (RAL) or atazanavir/ritonavir (ATV/r) both with tenofovir/emtricitabine in a predominantly African American indigent patient population in Houston, Texas. Results from 17 patients at 48 weeks (wk); 9 in the RAL group and 8 in the ATV/r group were available for analyses. We evaluated CD4+ count, CD4%, HIV RNA viral load (VL) levels, and lipid profile at wk 0, 6, 14, 30, and 48. IL-6 and homocysteine levels were available at wk 0 and 48. Among the lipid panel between the 2 groups, triglycerides became statistically significantly lower in the raltegravir group at 14 weeks and persisted at a lower level through 48 wk. There were no significant differences in CD4+ cell count, CD4%, log VL, total cholesterol, LDL, HDL, IL-6, and homocyseine levels. Both RAL and ATV/r in combination with tenofovir/emtricitabine provide similar immunologic and virologic efficacy. There was a slight difference observed in changes in triglyceride levels but other lipid changes were similar. IL-6 and homocystine levels changed to a similar degree with these potent antiretroviral regimens.

KW - Antiretroviral therapy

KW - Biomarkers

KW - Lipid levels

KW - Minority population

KW - Naive therapy

UR - http://www.scopus.com/inward/record.url?scp=84879831264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879831264&partnerID=8YFLogxK

U2 - 10.4172/2155-6113.1000192

DO - 10.4172/2155-6113.1000192

M3 - Article

VL - 4

JO - Journal of AIDS and Clinical Research

JF - Journal of AIDS and Clinical Research

SN - 2155-6113

IS - 2

ER -